ScinoPharm
ScinoPharm is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at ScinoPharm.
ScinoPharm is a company.
Key people at ScinoPharm.
Key people at ScinoPharm.
ScinoPharm Taiwan, Ltd. (TPE:1789) is a Taiwan-based pharmaceutical company specializing in the research, development, production, and sale of active pharmaceutical ingredients (APIs), primarily serving pharmaceutical companies globally in Taiwan, Asia, Europe, the US, India, and beyond.[1][2][3] It offers a range of services including custom synthesis of small molecules, peptides, nucleic acids, protein drugs, complex natural molecules, generic API manufacturing, and CDMO/CRAM services for clinical to commercial-stage APIs, intermediates, sterile injectables, and formulation development.[1][2][3][5] With 540 employees and headquarters in Tainan City, the company reported trailing twelve-month revenue of NT$3.19 billion and net earnings of NT$193 million as of recent data, showing strong financial health amid expansion into formulation and emerging markets.[1][3]
Recent growth highlights include 36% YoY revenue increase to NT$883 million in Q1 2024, with net profit up 233%; full-year 2024 revenue of NT$3.406 billion (7% growth) and net profit of NT$339 million (18% rise); and H1 2024 revenue of NT$1.646 billion with NT$215 million post-tax profit, alongside zero-deficiency US FDA and ANVISA inspections for its plants and China subsidiary.[5]
Founded in 1997 and headquartered in Tainan City, Taiwan, ScinoPharm Taiwan emerged as a specialist in API development and manufacturing amid Asia's rising role in global pharma supply chains.[1][2][6] The company built its foundation on high-barrier technologies like peptide synthesis and complex molecule production, evolving from custom synthesis to a full-service CDMO with cGMP facilities supporting early-phase R&D for branded and generic drugs.[2][6] Key leadership includes Chairman and Chief Strategy Officer Chih-Hsien Lo (since 2010) and CEO Li-An Lu, guiding its strategic alliances, such as with Baxter International for an antiemetic cancer drug.[1][4] Pivotal moments include passing rigorous US FDA inspections with zero deficiencies and expanding into injectables and oligonucleotides, solidifying its global footprint.[5]
ScinoPharm stands out in the competitive CDMO landscape through specialized capabilities and operational excellence:
ScinoPharm rides the wave of global API outsourcing and CDMO growth, fueled by pharma giants shifting complex manufacturing to Asia for cost efficiencies amid supply chain disruptions and rising R&D demands post-COVID.[2][5] Timing aligns with surging needs for high-barrier molecules in oncology, biologics, and injectables—areas where Western CDMOs face capacity constraints—while Taiwan's stable geopolitics and tech ecosystem provide advantages over China-centric players.[1][5] Market forces like generic drug booms, peptide/oligonucleotide therapies for cancer and rare diseases, and regulatory pressures favor its cGMP expertise and inspection successes, reducing client risks.[3][5] It influences the ecosystem by enabling faster drug commercialization for partners, bolstering Taiwan's biotech hub status, and bridging branded/generic sectors globally.[2][6]
ScinoPharm is poised for accelerated growth through CDMO expansion, formulation capabilities, and emerging market penetration, targeting sustained double-digit revenue gains amid biotech funding rebounds and complex API demand.[5] Trends like AI-driven drug discovery, personalized medicines, and supply chain diversification will amplify its role, potentially elevating market cap beyond NT$13.48 billion via new contracts and tech platforms.[3][5] Influence may evolve toward leadership in Asian high-value CDMOs, with risks tied to regulatory shifts or competition, but its track record positions it to capture outsized value in a fragmented market—echoing its origin as a 1997 innovator now scaling globally.[1][2]
